Market News & Trends
Apellis Dosed First Patient in Phase 3 Study
Apellis Pharmaceuticals Inc.recently announced the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2…
Passage Bio Closes $110-Million Series B Financing
Passage Bio recently announced the closing of a $110-million Series B financing. The financing round was led by Access Biotechnology with participation from existing investors,…
Kintai Therapeutics Announces Collaborations With Leading Academic Centers
Kintai Therapeutics recently announced it has established new collaborations with leading academic institutions to identify novel molecules that play a fundamental role in microbe to…
PCI Strengthens Position in Europe With Investment in Ireland
PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence…
Adaptimmune & Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products
Adaptimmune Therapeutics plc and Noile-Immune Biotech, Inc. recently announced they will co-develop next-generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (proliferation inducing and migration enhancing) technology,…
Ivy Brain Tumor Center & Salarius Pharmaceuticals Launch Collaborative Partnership
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. recently announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat,…
Aptinyx Presents Data Demonstrating Positive Activity on Cognitive Performance & Biomarkers in a Preclinical Model
Aptinyx Inc. recently announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. The product candidate demonstrated positive recovery of performance on…